A BET inhibitor (RVX-208) that suppresses stress-response gene transcription in perivascular fat restores blood vessel relaxation and reduces inflammatory markers in patients with obesity and hypertension. This approach targets the signaling interface between fat and vessel tissue rather than individual inflammatory molecules, demonstrating that perivascular adipose tissue dysfunction is a primary driver of endothelial impairment in cardiometabolic disease.
Key Points
- BET inhibition restores nitric oxide availability and vessel relaxation capacity
- Perivascular fat switches from protective to harmful in disease state
- Effect requires intact fat tissue; hexokinase-2 downregulation is key mechanism
Longevity Analysis
Endothelial dysfunction is an early, measurable hallmark of cardiovascular aging and a precursor to atherosclerotic disease. This work identifies perivascular adipose tissue as a modifiable control point—not merely a passive bystander but an active regulator of vessel health through gene expression patterns. The ability to reorient the vascular-fat interface from a pro-inflammatory to a pro-relaxation state, especially by dampening upstream stress signals rather than blocking individual cytokines, suggests a more durable intervention strategy. For individuals with cardiometabolic risk, restoring the tissue dialogue that preserves vessel compliance becomes a tangible target, one that addresses both the structural remodeling and the metabolic dysregulation that accelerate cardiovascular aging.
Original published by LifeSpan.io, by Arkadi Mazin.